Monday, November 8, 2021

Alnylam’s RNAi therapeutic Oxlumo gets EU green light

Alnylam Pharmaceuticals has scored an approval from the European Commission for its RNAi therapeutic Oxlumo, for the treatment of primary hyperoxaluria type 1 (PH1) in all age groups.

Oxlumo (lumasiran), an RNAi therapeutic, is designed to target the hydroxyacid oxidase 1 (HAO1) mRNA that encodes glycolate oxidase (GO) – an enzyme upstream of the disease-causing defect in PH1.

The degradation of the HAO1 mRNA and reduction in the synthesis of GO helps to stop the production of oxalate, the toxic metabolite that ‘directly contributes’ to causing PH1.

The EU approval is based on results from the phase III ILLUMINATE-A and ILLUMINATE-B of Oxlumo.

In the ILLUMINATE-A study, conducted in adults and children six years or older, Oxlumo treatment lead to a 53% reduction in urinary oxalate compared to placebo and a 65% mean reduction in urinary oxalate relative to baseline.

The ILLUMINATE-B, which evaluated Oxlumo in infants and children under the age of six years, scored similar efficacy and safety results to ILLUMINATE-A.

“Prior to now there have been no approved treatment options for PH1 in Europe, so this is a potentially life-changing milestone for people diagnosed with this ultra-rare, debilitating disease – many of whom are infants and children – and their families,” said John Maraganore, chief executive officer, Alnylam Pharmaceuticals.

“Oxlumo will address the urgent unmet need that exists for patients with PH1 and its approval today marks our continued commitment to rare disease communities,” he added.

PH1 is an ultra-rare disease characterised by excessive oxalate production, which can cause life threatening end-stage renal disease as well as other systemic complications.

If PH1 goes untreated, it can lead to progressive kidney damage – patients with advanced kidney disease require intensive dialysis to help filter waste products, including oxalate, from the blood.

Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...